Gilead Sciences (Nasdaq:GILD), Abbott Labs (NYSE:ABT), Alliance Data Systems Corporation (NYSE:ADS), Blue Nile (Nasdaq:NILE) and Bristol-Myers Squibb

AIDS Healthcare Foundation (AHF) launched a campaign today to educate employees and neighbors of Gilead Sciences, Inc. over the high price of its key AIDS drugs, such as Atripla, which are putting a strain on state cash-strapped AIDS Drug Assistance Programs (ADAPs).

BURLINGTON, Mass., Oct.

WALTHAM, Mass., June 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of HIV, Gilead and Tibotec (a wholly owned subsidiary of Johnson & Johnson) remain on track to launch three novel treatment options in the next two years - Gilead's Quad (a four drug, one pill, once-daily, regimen), Tibotec's rilpivirine and Gilead/Tibotec's rilpivirine/emtricitabine/tenofovir fixed-dose combination product.

ABBOTT PARK, Ill., April 28 /PRNewswire/ -- Abbott announced today that the U.S. Food and Drug Administration (FDA) approved once-daily dosing of Kaletra® (lopinavir/ritonavir) for adult patients with HIV who have previously taken antiretroviral therapy.